Press releases
- Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
- PacBio Grants Equity Incentive Award to New Employee
- PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions
- PacBio to Present at Upcoming Investor Conferences
- PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
- Experiential Marketing Firm VOLO Events Agency Wins Best Event Technology Award for PacBio Product Launch
- PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale
- PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions
- TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors
- PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.35 |
---|---|
High | 3.35 |
Low | 3.35 |
Bid | -- |
Offer | -- |
Previous close | 3.35 |
Average volume | 1.06k |
---|---|
Shares outstanding | 267.95m |
Free float | 260.41m |
P/E (TTM) | -- |
Market cap | 1.00bn USD |
EPS (TTM) | -1.21 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:05 BST.
More ▼